Medical

Results from a Phase 1 trial of an inhaled version of CanSino Biologic's Ad5-nCoV vaccine against COVID-19 have been published online in The Lancet Infectious Diseases. The study enrolled 130 healthy volunteers who got either intramuscular Ad5-nCoV, two doses of aerosolized vaccine, or IM vaccine with an aerosolized booster and found that the nebulized vaccine was … [Read more...] about Positive results for Phase 1 trial of CanSinoBio inhaled COVID-19 vaccine

Preclinical studies by researchers from the LKS Faculty of Medicine at The University of Hong Kong have demonstrated that a dry powder formulation of tamibarotene delivered to the lungs of hamster and mice has broad activity against respiratory viruses, including SARS-CoV-2, MERS-CoV, and influenza A H1N1. Results from the studies were published in Advanced … [Read more...] about Inhaled dry powder tamibarotene effective against respiratory viruses in preclinical studies

Sorrento Therapeutics has initiated a Phase 2 trial of its CoviDrops intranasal neutralizing antibody in COVID-19 patients in the UK, the company said. The trial is expected to enroll 350 COVID-19 patients who have mild symptoms or are asymptomatic who will get either 10 mg or 20 mg of CoviDrops via nasal instillation or placebo. Treatment and assessment will take … [Read more...] about Sorrento initiates Phase 2 trial of its intranasal neutralizing antibody against COVID-19

Meissa Vaccines said that a SARS-CoV-2 challenge test of its MV-014-212 intranasal live attenuated vaccine candidate in non-human primates demonstrated similar efficacy for a single dose compared to currently available vaccines, and the intranasal vaccine stimulated both mucosal and systemic antibodies. According to the company, the vaccine generated antibodies able … [Read more...] about Meissa announces results of preclinical testing of its intranasal COVID-19 vaccine, Phase 1 trial update

AIM ImmunoTech has announced a planned Phase 2a human challenge trial of intranasal Ampligen rintatolimod against human rhinovirus and influenza. The company suggested that "Success against these common viruses could also indicate that an Ampligen prophylaxis could help blunt the spread of infection from lethal coronaviruses, as well as other serious viruses." The … [Read more...] about AIM ImmunoTech announces planned human challenge trial of intranasal Ampligen against rhinovirus and flu

Opiant Pharmaceuticals said that a PK study of its OPNT003 intranasal nalmefene, which it is developing for opioid overdose, demonstrated that the Tmax of the nasal formulation was about 15 minutes, similar to that shown in a previous pilot study, and Cmax was slightly higher than for an intramuscular injection of nalmefene and higher than in the pilot study. The … [Read more...] about Opiant announces positive results from PK study of OPNT003 intranasal nalmefene

Anindya Roy, a researcher at the University of Washington Institute for Protein Design (IPD), has received a $250,000 grant from Washington Research Foundation (WRF) for continued development of an inhaled miniprotein binder for the treatment of idiopathic pulmonary fibrosis (IPF), WRF has announced. According to WRF, Roy's miniprotein binds to the αvβ6 integrin, … [Read more...] about Washington Research Foundation awards grant for development of inhaled miniprotein for IPF

Atossa Therapeutics said that the Human Research Ethics Committee (HREC) of the Australian National Health and Medical Research Council (NHMRC) has okayed a Phase 1/2a clinical study of the company's nebulized AT-H201, which is "is a proprietary combination of two drugs previously approved by the FDA to treat other diseases and by other administration routes." The … [Read more...] about Atossa announces Phase 1/2a study of nebulized AT-H201